These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

906 related items for PubMed ID: 29090673

  • 1. PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications.
    Giovacchini G, Giovannini E, Riondato M, Ciarmiello A.
    Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 4. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M.
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [Abstract] [Full Text] [Related]

  • 5. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer.
    Meyrick DP, Asokendaran M, Skelly LA, Lenzo NP, Henderson A.
    Nucl Med Commun; 2017 Nov; 38(11):956-963. PubMed ID: 28922335
    [Abstract] [Full Text] [Related]

  • 6. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
    Eissa A, Elsherbiny A, Coelho RF, Rassweiler J, Davis JW, Porpiglia F, Patel VR, Prandini N, Micali S, Sighinolfi MC, Puliatti S, Rocco B, Bianchi G.
    Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
    [Abstract] [Full Text] [Related]

  • 7. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
    Kabasakal L, Demirci E, Nematyazar J, Akyel R, Razavi B, Ocak M, Aygun A, Obek C, Kural AR.
    Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
    [Abstract] [Full Text] [Related]

  • 8. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
    Barbaud M, Frindel M, Ferrer L, Le Thiec M, Rusu D, Rauscher A, Maucherat B, Baumgartner P, Fleury V, Colombié M, Thierry-Morel A, Kraeber-Bodéré F, Campion L, Rousseau C.
    Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic Accuracy of 68Ga-PSMA PET/CT for Initial Detection in Patients With Suspected Prostate Cancer: A Systematic Review and Meta-Analysis.
    Satapathy S, Singh H, Kumar R, Mittal BR.
    AJR Am J Roentgenol; 2021 Mar; 216(3):599-607. PubMed ID: 32755196
    [Abstract] [Full Text] [Related]

  • 10. Clinicopathological predictors of positive 68Ga-PSMA-11 PET/CT in PSA-only recurrence of localized prostate cancer following definitive therapy.
    Aydin AM, Haberal B, Artykov M, Bilen CY, Yazici S.
    Ann Nucl Med; 2019 May; 33(5):326-332. PubMed ID: 30778860
    [Abstract] [Full Text] [Related]

  • 11. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
    Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş MG, Çermik TF.
    Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
    [Abstract] [Full Text] [Related]

  • 12. Multiphasic 68Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients.
    Beheshti M, Manafi-Farid R, Geinitz H, Vali R, Loidl W, Mottaghy FM, Langsteger W.
    J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of 68Ga-PSMA PET/CT on Survival and Management in Prostate Cancer.
    Algın E, Okudan B, Açıkgöz Y, Sayan H, Bal Ö, Seven B.
    Curr Med Imaging; 2024 Oct; 20():e15734056276494. PubMed ID: 38284703
    [Abstract] [Full Text] [Related]

  • 15. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
    Lin CY, Lee MT, Lin CL, Kao CH.
    Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999
    [Abstract] [Full Text] [Related]

  • 16. Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
    Thin P, Hotta M, Gafita A, Grogan T, Czernin J, Calais J, Sonni I.
    J Nucl Med; 2024 Oct 01; 65(10):1571-1576. PubMed ID: 39168522
    [Abstract] [Full Text] [Related]

  • 17. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
    Raju S, Sharma A, Patel C, Sahoo R, Das CJ, Kumar S, Sharma A, Kumar R.
    Nucl Med Commun; 2020 Nov 01; 41(11):1183-1188. PubMed ID: 32796451
    [Abstract] [Full Text] [Related]

  • 18. 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients.
    Caroli P, Sandler I, Matteucci F, De Giorgi U, Uccelli L, Celli M, Foca F, Barone D, Romeo A, Sarnelli A, Paganelli G.
    Eur J Nucl Med Mol Imaging; 2018 Nov 01; 45(12):2035-2044. PubMed ID: 29922948
    [Abstract] [Full Text] [Related]

  • 19. A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT-Protocol design and rationale.
    Alberts I, Bütikofer L, Rominger A, Afshar-Oromieh A.
    PLoS One; 2022 Nov 01; 17(7):e0270269. PubMed ID: 35853017
    [Abstract] [Full Text] [Related]

  • 20. Comparison of 68Ga-PSMA-I/T PET-CT and Multiparametric MRI for Locoregional Staging of Prostate Cancer Patients: A Pilot Study.
    Çelen S, Gültekin A, Özlülerden Y, Mete A, Sağtaş E, Ufuk F, Yüksel D, Yağcı B, Zümrütbaş AE.
    Urol Int; 2020 Nov 01; 104(9-10):684-691. PubMed ID: 32750695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.